177 related articles for article (PubMed ID: 35990626)
1. CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E; Giordano Attianese GMP; Coukos G; Irving M
Front Immunol; 2022; 13():951143. PubMed ID: 35990626
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside.
Heinzelbecker J; Fauskanger M; Jonson I; Krengel U; Løset GÅ; Munthe L; Tveita A
Front Immunol; 2024; 15():1331345. PubMed ID: 38370401
[TBL] [Abstract][Full Text] [Related]
3. Cytofluorimetric evaluation of N-glycolylated GM3 ganglioside expression on murine leukocytes.
Miranda A; de León J; Roque-Navarro L; Fernández LE
Immunol Lett; 2011 Jun; 137(1-2):38-45. PubMed ID: 21324343
[TBL] [Abstract][Full Text] [Related]
4. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.
Casadesús AV; Fernández-Marrero Y; Clavell M; Gómez JA; Hernández T; Moreno E; López-Requena A
Glycoconj J; 2013 Oct; 30(7):687-99. PubMed ID: 23547010
[TBL] [Abstract][Full Text] [Related]
5. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.
Fernández-Marrero Y; Roque-Navarro L; Hernández T; Dorvignit D; Molina-Pérez M; González A; Sosa K; López-Requena A; Pérez R; de Acosta CM
Immunobiology; 2011 Dec; 216(12):1239-47. PubMed ID: 21802167
[TBL] [Abstract][Full Text] [Related]
6. Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T-Cell Activation at the Immunological Synapse.
Zang H; Siddiqui M; Gummuluru S; Wong WW; Reinhard BM
ACS Nano; 2022 Nov; 16(11):18408-18420. PubMed ID: 36282488
[TBL] [Abstract][Full Text] [Related]
7. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.
de Leòn J; Fernández A; Mesa C; Clavel M; Fernández LE
Cancer Immunol Immunother; 2006 Apr; 55(4):443-50. PubMed ID: 16208470
[TBL] [Abstract][Full Text] [Related]
8. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity.
Roque-Navarro L; Chakrabandhu K; de León J; Rodríguez S; Toledo C; Carr A; de Acosta CM; Hueber AO; Pérez R
Mol Cancer Ther; 2008 Jul; 7(7):2033-41. PubMed ID: 18645013
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
10. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function.
de León J; Fernández A; Clavell M; Labrada M; Bebelagua Y; Mesa C; Fernández LE
Int Immunol; 2008 Apr; 20(4):591-600. PubMed ID: 18310617
[TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
13. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
14. Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.
Palomo AG; Medinilla AL; Segatori V; Barroso MDC; Blanco R; Gabri MR; Pérez AC; Monzón KL
Oncotarget; 2018 May; 9(35):24069-24080. PubMed ID: 29844873
[TBL] [Abstract][Full Text] [Related]
15. Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.
Gabri MR; Otero LL; Gomez DE; Alonso DF
J Exp Clin Cancer Res; 2009 Dec; 28(1):146. PubMed ID: 19951433
[TBL] [Abstract][Full Text] [Related]
16. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
18. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
19. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
